Obsessive-compulsive symptoms in patients with schizophrenia: Relationships with olanzapine pharmacological parameters, psychopathology, and quality of life

Tzu Hua Wu, Chih Chiang Chiu, Po Yu Chen, Ming Chyi Huang, Chun Hsin Chen, Winston W. Shen, Mong Liang Lu

Research output: Contribution to journalArticle

Abstract

Obsessive-compulsive symptoms (OCS) occur in a substantial portion of schizophrenia patients and have significant impacts on clinical course. This study was intended to investigate the relationships of OCS with pharmacological parameters of olanzapine, psychopathology, and quality of life. Totally 151 schizophrenia patients were recruited, and rated using Yale-Brown Obsessive-Compulsive scale (YBOCS), Positive and Negative Syndrome Scale (PANSS), Montgomery-Åsberg Depression Rating Scale (MADRS), and World Health Organization Questionnaire on Quality of Life: Short Form (WHOQOL-BREF). The concentrations of olanzapine and N-desmethylolanzapine were determined by HPLC. Twenty-five patients (16.6%) revealed the presence of OCS. OCS group had significantly higher olanzapine dose, more numbers of past hospitalizations, higher PANSS total, positive, negative, and general psychopathology scores, and higher MADRS score than those in non-OCS group. The WHOQOL-BREF physical subscale score in schizophrenia patients with OCS was significantly lower. Olanzapine dose, PANSS score, and MADRS score were significantly correlated with YBOCS score. Our findings highlight that OCS is highly prevalent in schizophrenia patients under olanzapine treatment, especially those at high doses. Schizophrenia patients with OCS had higher severity of psychotic and depressive symptoms and poorer quality of life. Clinicians should monitor OCS in patients with schizophrenia receiving olanzapine treatment.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalPsychiatry Research
Volume276
DOIs
Publication statusPublished - Jun 1 2019

Fingerprint

olanzapine
Psychopathology
Schizophrenia
Quality of Life
Pharmacology
Depression
Hospitalization
High Pressure Liquid Chromatography

Keywords

  • Depression
  • Obsessive-compulsive symptoms
  • Olanzapine
  • Psychopathology
  • Quality of life
  • Yale-Brown Obsessive-Compulsive scale

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

@article{6bea8ff9dcc5459aa5706ee27baa13d8,
title = "Obsessive-compulsive symptoms in patients with schizophrenia: Relationships with olanzapine pharmacological parameters, psychopathology, and quality of life",
abstract = "Obsessive-compulsive symptoms (OCS) occur in a substantial portion of schizophrenia patients and have significant impacts on clinical course. This study was intended to investigate the relationships of OCS with pharmacological parameters of olanzapine, psychopathology, and quality of life. Totally 151 schizophrenia patients were recruited, and rated using Yale-Brown Obsessive-Compulsive scale (YBOCS), Positive and Negative Syndrome Scale (PANSS), Montgomery-{\AA}sberg Depression Rating Scale (MADRS), and World Health Organization Questionnaire on Quality of Life: Short Form (WHOQOL-BREF). The concentrations of olanzapine and N-desmethylolanzapine were determined by HPLC. Twenty-five patients (16.6{\%}) revealed the presence of OCS. OCS group had significantly higher olanzapine dose, more numbers of past hospitalizations, higher PANSS total, positive, negative, and general psychopathology scores, and higher MADRS score than those in non-OCS group. The WHOQOL-BREF physical subscale score in schizophrenia patients with OCS was significantly lower. Olanzapine dose, PANSS score, and MADRS score were significantly correlated with YBOCS score. Our findings highlight that OCS is highly prevalent in schizophrenia patients under olanzapine treatment, especially those at high doses. Schizophrenia patients with OCS had higher severity of psychotic and depressive symptoms and poorer quality of life. Clinicians should monitor OCS in patients with schizophrenia receiving olanzapine treatment.",
keywords = "Depression, Obsessive-compulsive symptoms, Olanzapine, Psychopathology, Quality of life, Yale-Brown Obsessive-Compulsive scale",
author = "Wu, {Tzu Hua} and Chiu, {Chih Chiang} and Chen, {Po Yu} and Huang, {Ming Chyi} and Chen, {Chun Hsin} and Shen, {Winston W.} and Lu, {Mong Liang}",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.psychres.2019.03.007",
language = "English",
volume = "276",
pages = "1--5",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Obsessive-compulsive symptoms in patients with schizophrenia

T2 - Relationships with olanzapine pharmacological parameters, psychopathology, and quality of life

AU - Wu, Tzu Hua

AU - Chiu, Chih Chiang

AU - Chen, Po Yu

AU - Huang, Ming Chyi

AU - Chen, Chun Hsin

AU - Shen, Winston W.

AU - Lu, Mong Liang

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Obsessive-compulsive symptoms (OCS) occur in a substantial portion of schizophrenia patients and have significant impacts on clinical course. This study was intended to investigate the relationships of OCS with pharmacological parameters of olanzapine, psychopathology, and quality of life. Totally 151 schizophrenia patients were recruited, and rated using Yale-Brown Obsessive-Compulsive scale (YBOCS), Positive and Negative Syndrome Scale (PANSS), Montgomery-Åsberg Depression Rating Scale (MADRS), and World Health Organization Questionnaire on Quality of Life: Short Form (WHOQOL-BREF). The concentrations of olanzapine and N-desmethylolanzapine were determined by HPLC. Twenty-five patients (16.6%) revealed the presence of OCS. OCS group had significantly higher olanzapine dose, more numbers of past hospitalizations, higher PANSS total, positive, negative, and general psychopathology scores, and higher MADRS score than those in non-OCS group. The WHOQOL-BREF physical subscale score in schizophrenia patients with OCS was significantly lower. Olanzapine dose, PANSS score, and MADRS score were significantly correlated with YBOCS score. Our findings highlight that OCS is highly prevalent in schizophrenia patients under olanzapine treatment, especially those at high doses. Schizophrenia patients with OCS had higher severity of psychotic and depressive symptoms and poorer quality of life. Clinicians should monitor OCS in patients with schizophrenia receiving olanzapine treatment.

AB - Obsessive-compulsive symptoms (OCS) occur in a substantial portion of schizophrenia patients and have significant impacts on clinical course. This study was intended to investigate the relationships of OCS with pharmacological parameters of olanzapine, psychopathology, and quality of life. Totally 151 schizophrenia patients were recruited, and rated using Yale-Brown Obsessive-Compulsive scale (YBOCS), Positive and Negative Syndrome Scale (PANSS), Montgomery-Åsberg Depression Rating Scale (MADRS), and World Health Organization Questionnaire on Quality of Life: Short Form (WHOQOL-BREF). The concentrations of olanzapine and N-desmethylolanzapine were determined by HPLC. Twenty-five patients (16.6%) revealed the presence of OCS. OCS group had significantly higher olanzapine dose, more numbers of past hospitalizations, higher PANSS total, positive, negative, and general psychopathology scores, and higher MADRS score than those in non-OCS group. The WHOQOL-BREF physical subscale score in schizophrenia patients with OCS was significantly lower. Olanzapine dose, PANSS score, and MADRS score were significantly correlated with YBOCS score. Our findings highlight that OCS is highly prevalent in schizophrenia patients under olanzapine treatment, especially those at high doses. Schizophrenia patients with OCS had higher severity of psychotic and depressive symptoms and poorer quality of life. Clinicians should monitor OCS in patients with schizophrenia receiving olanzapine treatment.

KW - Depression

KW - Obsessive-compulsive symptoms

KW - Olanzapine

KW - Psychopathology

KW - Quality of life

KW - Yale-Brown Obsessive-Compulsive scale

UR - http://www.scopus.com/inward/record.url?scp=85064078521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064078521&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2019.03.007

DO - 10.1016/j.psychres.2019.03.007

M3 - Article

AN - SCOPUS:85064078521

VL - 276

SP - 1

EP - 5

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

ER -